Diagnosis, prognosis and therapeutic control of malignant diseases using PLA2R1 methylation analysis
The invention relates to the field of medicine, specifically to the diagnostics, prognosis and therapy control of tumour diseases. The invention is based on the hitherto unknown epigenetic silencing, discovered by chance by the inventors, of the phospholipase-A2-receptor-1-coding gene in leukaemia cells and in patients suffering from leukaemias and solid tumours. Based on this finding, the invention provides methods and a kit with which the degree of methylation of the phospholipase-A2-receptor-1 gene in an isolated sample of the patient is determined.
Property right: DE102010031354B3; WO002012007462A1
Further Information: PDF
GWT-TUD GmbH; FB Sächsische PatentVerwertungsAgentur (SPVA)
Phone: +49 351 25933 120
Contact
Beate-Victoria Ermisch
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Properties of new materials for microchips
… can now be measured well. Reseachers of Delft University of Technology demonstrated measuring performance properties of ultrathin silicon membranes. Making ever smaller and more powerful chips requires new ultrathin…
Floating solar’s potential
… to support sustainable development by addressing climate, water, and energy goals holistically. A new study published this week in Nature Energy raises the potential for floating solar photovoltaics (FPV)…
Skyrmions move at record speeds
… a step towards the computing of the future. An international research team led by scientists from the CNRS1 has discovered that the magnetic nanobubbles2 known as skyrmions can be…
